BR0009864A - Compound, pharmaceutical composition, methods for the treatment of diseases, for the treatment and / or prevention of conditions mediated by nuclear receptors and for the treatment and / or prevention of diabetes and / or obesity, and, use of a compound - Google Patents
Compound, pharmaceutical composition, methods for the treatment of diseases, for the treatment and / or prevention of conditions mediated by nuclear receptors and for the treatment and / or prevention of diabetes and / or obesity, and, use of a compoundInfo
- Publication number
- BR0009864A BR0009864A BR0009864-7A BR0009864A BR0009864A BR 0009864 A BR0009864 A BR 0009864A BR 0009864 A BR0009864 A BR 0009864A BR 0009864 A BR0009864 A BR 0009864A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- prevention
- compound
- conditions mediated
- obesity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA O TRATAMENTO DE DOENçAS, PARA O TRATAMENTO E/OU PREVENçãO DE CONDIçõES MEDIADAS PELOS RECEPTORES NUCLEARES E PARA O TRATAMENTO E/OU PREVENçãO DE DIABETE E/OU OBESIDADE, E, USO DE UM COMPOSTO". A presente invenção diz respeito a compostos da fórmula geral (I). Os compostos são úteis no tratamento e/ou na prevenção de condições mediadas por receptores nucleares, em particular os Receptores Ativados pelo Proliferador de Perozisoma (PPAR)."COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR THE TREATMENT OF DISEASES, FOR THE TREATMENT AND / OR PREVENTION OF CONDITIONS MEDIATED BY NUCLEAR RECEPTORS AND FOR THE TREATMENT AND / OR PREVENTION OF DIABETES AND / OR OBESITY, AND, USE OF A COMPOSITION. The present invention relates to compounds of the general formula (I). The compounds are useful in the treatment and / or prevention of conditions mediated by nuclear receptors, in particular Perozisoma Proliferator Activated Receptors (PPAR).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199900533 | 1999-04-20 | ||
PCT/DK2000/000190 WO2000063153A1 (en) | 1999-04-20 | 2000-04-17 | New compounds, their preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0009864A true BR0009864A (en) | 2002-01-08 |
Family
ID=8094620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0009864-7A BR0009864A (en) | 1999-04-20 | 2000-04-17 | Compound, pharmaceutical composition, methods for the treatment of diseases, for the treatment and / or prevention of conditions mediated by nuclear receptors and for the treatment and / or prevention of diabetes and / or obesity, and, use of a compound |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1171414A1 (en) |
JP (1) | JP2002542218A (en) |
KR (1) | KR20020005703A (en) |
CN (1) | CN1348439A (en) |
AU (1) | AU3958000A (en) |
BR (1) | BR0009864A (en) |
CA (1) | CA2367356A1 (en) |
CZ (1) | CZ20013558A3 (en) |
HU (1) | HUP0200807A3 (en) |
IL (1) | IL145789A0 (en) |
NO (1) | NO20015113L (en) |
PL (1) | PL351312A1 (en) |
RU (1) | RU2001131111A (en) |
TW (1) | TW553931B (en) |
WO (1) | WO2000063153A1 (en) |
ZA (1) | ZA200107983B (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6555577B1 (en) | 2000-01-28 | 2003-04-29 | Novo Nordisk A/S | Compounds, their preparation and use |
CN1396903A (en) * | 2000-01-28 | 2003-02-12 | 诺沃挪第克公司 | Novel compound, their preparation and use |
ES2253353T3 (en) | 2000-03-08 | 2006-06-01 | Novo Nordisk A/S | SERICO CHOLESTEROL REDUCTION. |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
US6869967B2 (en) | 2001-07-30 | 2005-03-22 | Novo Nordisk A/S | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives |
WO2003011834A1 (en) * | 2001-07-30 | 2003-02-13 | Novo Nordisk A/S | Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
CZ2004133A3 (en) * | 2001-07-30 | 2004-06-16 | Novo Nordisk A/S | Derivatives of vinyl carboxylic acid, pharmaceutical composition in which the derivative is comprised and use thereof |
EP1414785A1 (en) * | 2001-07-30 | 2004-05-06 | Novo Nordisk A/S | Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
EP2243776A1 (en) | 2001-10-12 | 2010-10-27 | High Point Pharmaceuticals, LLC | Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor |
EP1458382A1 (en) | 2001-12-21 | 2004-09-22 | Novo Nordisk A/S | Amide derivatives as gk activators |
US7015345B2 (en) | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
KR101116627B1 (en) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | Aryl carbonyl derivatives as therapeutic agents |
AU2003260282A1 (en) * | 2002-09-05 | 2004-03-29 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their therapeutical use |
AU2003273783C1 (en) * | 2002-10-28 | 2010-08-12 | Vtv Therapeutics Llc | Novel compounds and their use as PPAR-modulators |
US7129268B2 (en) * | 2002-10-28 | 2006-10-31 | Novo Nordisk A/S | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives |
CN100491316C (en) | 2002-10-28 | 2009-05-27 | 高点制药有限责任公司 | Novel compounds, their preparation and use |
EP1558571B1 (en) * | 2002-10-28 | 2010-06-02 | High Point Pharmaceuticals, LLC | Novel compounds useful in treating ppar mediated diseases |
AU2003287912A1 (en) * | 2002-12-20 | 2004-07-14 | Novo Nordisk A/S | Dicarboxylic acid derivatives as ppar-agonists |
US7816385B2 (en) | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
WO2004101505A1 (en) | 2003-05-14 | 2004-11-25 | Novo Nordisk A/S | Novel compounds for treatment of obesity |
ES2378435T3 (en) | 2003-09-19 | 2012-04-12 | Janssen Pharmaceutica N.V. | �? 4 - ((phenoxyalkyl) thio) -phenoxyacetic acids and the like |
CA2539596A1 (en) | 2003-09-30 | 2005-04-07 | Kilian Waldemar Conde-Frieboes | Melanocortin receptor agonists |
WO2005056036A2 (en) | 2003-12-09 | 2005-06-23 | Novo Nordisk A/S | Regulation of food preference using glp-1 agonists |
MXPA06007667A (en) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaryl-ureas and their use as glucokinase activators. |
EP1758856A2 (en) | 2004-05-04 | 2007-03-07 | Novo Nordisk A/S | Indole derivatives for the treatment of obesity |
WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
ATE486838T1 (en) * | 2004-05-05 | 2010-11-15 | High Point Pharmaceuticals Llc | NEW COMPOUNDS, THEIR PRODUCTION AND USE |
CN1950078A (en) | 2004-06-11 | 2007-04-18 | 诺和诺德公司 | Counteracting drug-induced obesity using glp-1 agonists |
CN101060856B (en) | 2004-11-22 | 2011-01-19 | 诺和诺德公司 | Soluble, stable insulin-containing formulations with a protamine salt |
BRPI0518798A2 (en) | 2004-12-03 | 2008-12-09 | Transtech Pharma Inc | compound, pharmaceutical composition, and methods for treating type II diabetes and for treating a condition or disorder |
FR2882359A1 (en) * | 2005-02-24 | 2006-08-25 | Negma Lerads Soc Par Actions S | New phenyl compounds are peroxisome proliferator activated receptor activators useful to treat hyperlipidemia and atherosclerosis |
WO2006091047A1 (en) * | 2005-02-25 | 2006-08-31 | Heonjoong Kang | Thiazole derivatives as ppar delta ligands and their manufacturing process |
ES2375929T3 (en) | 2005-07-04 | 2012-03-07 | High Point Pharmaceuticals, Llc | HISTAMINE RECEIVER ANTAGONISTS H3. |
AU2006268589B2 (en) | 2005-07-14 | 2011-09-29 | Vtv Therapeutics Llc | Urea glucokinase activators |
WO2007015805A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | 1-amino linked compounds |
PT1951658E (en) | 2005-11-17 | 2012-11-12 | Lilly Co Eli | Glucagon receptor antagonists, preparation and therapeutic uses |
NZ568488A (en) | 2005-12-22 | 2011-07-29 | High Point Pharmaceuticals Llc | Phenoxy acetic acids as PPAR delta activators |
AU2007229492B2 (en) | 2006-03-28 | 2011-11-03 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
WO2007137968A1 (en) | 2006-05-29 | 2007-12-06 | High Point Pharmaceuticals, Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
WO2008059025A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
WO2008059026A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
BR112012021231A2 (en) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product |
US20130012432A1 (en) | 2010-02-26 | 2013-01-10 | Novo Nordisk A/S | Peptides for Treatment of Obesity |
RU2559320C2 (en) | 2010-03-26 | 2015-08-10 | Ново Нордиск А/С | Novel glucagon analogues |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
EP2670368A4 (en) | 2011-02-03 | 2015-04-15 | Pharmedica Ltd | New oral dissolving films for insulin administration, for treating diabetes |
RU2013145013A (en) | 2011-03-28 | 2015-05-10 | Ново Нордиск А/С | NEW GLUCAGON ANALOGUES |
JP6352806B2 (en) | 2011-09-23 | 2018-07-04 | ノヴォ ノルディスク アー/エス | New glucagon analogues |
SI2986313T1 (en) | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
CN107915701B (en) * | 2016-10-10 | 2020-09-29 | 沈阳药科大学 | PPAR alpha/gamma dual agonist and application thereof |
US20200223889A1 (en) | 2017-03-15 | 2020-07-16 | Novo Nordisk A/S | Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor |
US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
BR112023001048A2 (en) | 2020-07-22 | 2023-04-04 | Reneo Pharmaceuticals Inc | CRYSTALLINE PPAR-DELTA AGONIST |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9508468A (en) * | 1994-07-29 | 1997-11-25 | Smithkline Beecham Plc | Compound process for the preparation of the same pharmaceutical composition processes for the treatment and / or prophylaxis of hyperglycemia in a human or non-human mammal and for the treatment of hyperlipidemia hypertension cardiovascular disease some eating disorders the treatment and / or prophylaxis of kidney disease prevention revers o stabilization or retardation of microalbuminuria progression in a human or non-human mammal use of the compound and intermediate compound |
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
DE69815008T2 (en) * | 1997-09-19 | 2004-04-01 | Ssp Co., Ltd. | Alpha-substituted phenylpropionic acid derivatives and medicaments containing them |
WO1999019313A1 (en) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
WO1999016758A1 (en) * | 1997-10-27 | 1999-04-08 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
AU1887999A (en) * | 1998-01-29 | 1999-08-16 | Dr. Reddy's Research Foundation | Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
EP1073643B1 (en) * | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
NZ504106A (en) * | 1998-05-27 | 2003-02-28 | Dr | Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them |
-
2000
- 2000-04-17 JP JP2000612250A patent/JP2002542218A/en active Pending
- 2000-04-17 IL IL14578900A patent/IL145789A0/en unknown
- 2000-04-17 PL PL00351312A patent/PL351312A1/en not_active Application Discontinuation
- 2000-04-17 HU HU0200807A patent/HUP0200807A3/en unknown
- 2000-04-17 EP EP00918725A patent/EP1171414A1/en not_active Withdrawn
- 2000-04-17 CA CA002367356A patent/CA2367356A1/en not_active Abandoned
- 2000-04-17 RU RU2001131111/04A patent/RU2001131111A/en not_active Application Discontinuation
- 2000-04-17 WO PCT/DK2000/000190 patent/WO2000063153A1/en not_active Application Discontinuation
- 2000-04-17 KR KR1020017013417A patent/KR20020005703A/en not_active Application Discontinuation
- 2000-04-17 CZ CZ20013558A patent/CZ20013558A3/en unknown
- 2000-04-17 BR BR0009864-7A patent/BR0009864A/en not_active IP Right Cessation
- 2000-04-17 AU AU39580/00A patent/AU3958000A/en not_active Abandoned
- 2000-04-17 CN CN00806561A patent/CN1348439A/en active Pending
- 2000-05-02 TW TW089108460A patent/TW553931B/en not_active IP Right Cessation
-
2001
- 2001-09-28 ZA ZA200107983A patent/ZA200107983B/en unknown
- 2001-10-19 NO NO20015113A patent/NO20015113L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200107983B (en) | 2002-05-29 |
PL351312A1 (en) | 2003-04-07 |
HUP0200807A2 (en) | 2002-07-29 |
KR20020005703A (en) | 2002-01-17 |
EP1171414A1 (en) | 2002-01-16 |
NO20015113L (en) | 2001-12-19 |
CN1348439A (en) | 2002-05-08 |
AU3958000A (en) | 2000-11-02 |
IL145789A0 (en) | 2002-07-25 |
HUP0200807A3 (en) | 2003-03-28 |
JP2002542218A (en) | 2002-12-10 |
TW553931B (en) | 2003-09-21 |
NO20015113D0 (en) | 2001-10-19 |
CA2367356A1 (en) | 2000-10-26 |
CZ20013558A3 (en) | 2002-05-15 |
RU2001131111A (en) | 2003-08-10 |
WO2000063153A1 (en) | 2000-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0009864A (en) | Compound, pharmaceutical composition, methods for the treatment of diseases, for the treatment and / or prevention of conditions mediated by nuclear receptors and for the treatment and / or prevention of diabetes and / or obesity, and, use of a compound | |
BR0107901A (en) | Compound, pharmaceutical composition, method for treating illness, for treating and / or preventing conditions mediated by nuclear receptors, and for the treatment and / or prevention of diabetes and / or obesity, use of a compound, and, method for treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance or obesity | |
BR0211122A (en) | Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt | |
BR0116370A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient. | |
BRPI0412893A (en) | compound, pharmaceutical composition, use of a compound, and methods for preventing, treating or ameliorating inflammatory diseases or conditions, or ophthalmic diseases or conditions, treating or ameliorating cancer, and for producing a compound | |
BR9810592A (en) | Compound, processes for preparing a compound, for treating or preventing diseases of the endocrine system and for the manufacture of a drug, pharmaceutical composition, and, use of a compound | |
BRPI9915985B8 (en) | 2-cyanopyrrolidines n-substituted, pharmaceutical composition comprising them and their use | |
BR0307351A (en) | Compound, pharmaceutical composition, method for treating a p38 kinase activity-mediated or cytokine-mediated condition or condition produced by p38 kinase activity, use of a compound, and process for preparing a compound | |
BR0215240A (en) | Calcium derivatives and their use in treating diseases | |
BRPI0113162B8 (en) | non-imidazole aryloxyalkylamine compounds and pharmaceutical composition comprising said compounds | |
BRPI0312398B8 (en) | substituted 1,3-diphenylprop-2-en-1-one derivative, process for preparing compounds, pharmaceutical composition and use of at least one substituted 1,3-diphenylprop-2-en-1-one derivative | |
BR0313266A (en) | Compounds, their preparation and use processes, pharmaceutical formulation and methods for preventing and / or treating a mglur5 receptor mediated disorder and inhibiting mglur5 receptor activation | |
BR0209468A (en) | Pharmaceutically acceptable compound or salts or solvates thereof, pharmaceutical composition, use of a compound, and method of treating an HPP-mediated disease or condition | |
BR0210711A (en) | Use of a compound, pharmaceutical composition, compound, and process for preparing a compound | |
BR0009486A (en) | Compounds containing an amide, use of those compounds, pharmaceutical composition, process for the prophylactic or therapeutic treatment of, type II diabetes and process for the preparation of the compounds | |
BRPI0409109A (en) | new compounds | |
KR970027098A (en) | Propiophenone Derivatives and Methods for Making the Same | |
BR0108679A (en) | New compounds | |
BR0209957A (en) | Compound, process for preparing a compound, pharmaceutical composition comprising a compound, use of such compound and process for the treatment and prophylaxis of arthritis, diabetes, eating disorders and obesity | |
BRPI0508051A (en) | heteroarylaminopyrazole derivatives usable for the treatment of diabetes | |
BR0211118A (en) | Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt | |
BRPI0417833A (en) | benzofuran derivatives which may be used for the prophylaxis or treatment of 5-ht6 receptor-related disorders | |
BR0212787A (en) | Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition | |
BRPI0407253A (en) | Heterocyclyl-3-sulfonylindazoles as ligands 5-hydroxytryptamine-6 process for their preparation, their uses in the preparation of a pharmaceutical composition and a pharmaceutical composition comprising said compounds | |
BR0215151A (en) | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A,8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009. |